Gastrointestinal side effects play a major role in these early discontinuations
GLP-1 receptor agonists are used to manage type 2 diabetes and obesity by stimulating insulin secretion, suppressing glucagon, and slowing gastric emptying
Additionally, GLP-1 slows down the emptying of the stomach, which helps people feel full longer, and it also reduces appetite by acting on the brain
If approved, it would be the first oral GLP-1 drug specifically indicated for obesity
Patients with risk factors such as obesity, extended diabetes duration, or specific medication use might need extra monitoring
In October 2024, we completed our IPO, which resulted in net proceeds of $302.8 million, net of total offering costs of $28.4 million